Clinical trials
Hematology clinical trials
Below are recruiting hematology clinical trials, each written for real people, not researchers. We’re tracking 574 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07169487RecruitingPhase 1
Methylene Blue for Side Effects of Cancer Immunotherapy
This trial tests if methylene blue can help people who develop side effects called CRS or ICANS after treatments like CAR-T cells or bispecific antibodies. It is a first-in-human study to find a safe dose.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07169500RecruitingPhase 1/Phase 2
CAR-T with or without stem cell transplant for young women with myeloma
This trial tests a new immune cell therapy (BCMA-CART) alone or combined with a stem cell transplant for women aged 18-55 with multiple myeloma. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–50 - NCT07165769RecruitingPhase 2
ZGR combo for newly diagnosed spleen lymphoma with large cells
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) for people newly diagnosed with splenic B-cell lymphoma that has large cells (prominent nucleoli). The goal is to see if this drug combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT05908409RecruitingPhase 1/Phase 2
Testing an investigational drug for blood cancers that came back
This Phase 1/2 trial tests IDP-121 in people with certain blood cancers that have returned or did not respond to available treatments. The goal is to find a safe dose and see whether the treatment can help control the cancer.
Santander, CantabriaAges 18 years+ - NCT06222164Recruiting
Using leftover patient samples for research
This study uses leftover blood, bone marrow, or tissue samples that were already sent to a specific lab (LabPMM) for testing. Researchers want to study these samples to learn more about diseases and improve future tests for patients.
San Diego, CaliforniaAges 18 years+ - NCT07147621Recruiting
Chemotherapy and thinking changes in blood cancer treatment
This study looks at whether chemotherapy for blood cancers like leukemia and lymphoma can affect thinking, memory, or concentration. It compares patients to a close family member or friend to see if any changes are related to the treatment.
Angers, Maine et LoireAges 18 years+ - NCT07154823Recruiting
Blood cancer registry study for biomarker discovery
This study collects samples and health information from people with certain blood cancers to learn more about the disease and find markers that may help guide future treatments. You will not receive a treatment from this study, but you may help advance research.
Iowa City, IowaAges birth+ - NCT07152041RecruitingPhase 3
Pediatric Ph+ B-ALL treatment trial
This trial tests a new treatment plan for children and teens newly diagnosed with a specific type of leukemia called Philadelphia chromosome-positive B-ALL. The goal is to see if the approach improves outcomes.
Hefei, AnhuiAges 1 month–18 years - NCT07151690RecruitingPhase 2
BCMA/CD3 bispecific antibody for newly diagnosed AL amyloidosis
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
TianjinAges 18 years+ - NCT07142239Recruiting
Blood markers in primary vs. secondary antiphospholipid syndrome
This study looks at three blood markers (MPV, PLR, and NLR) in people with antiphospholipid syndrome (APS) to see if they differ between primary APS (no other autoimmune disease) and secondary APS (with lupus or another autoimmune condition). It may help doctors better understand and manage APS.
Al Khārjah, Kharga OasisAges 18 years+ - NCT07133074RecruitingPhase 4
Testing penicillin allergy labels in blood cancer patients
This trial checks whether people with blood cancers who think they are allergic to penicillin or related antibiotics can safely take these medicines again. It aims to remove incorrect allergy labels to improve treatment options.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07126782RecruitingEarly Phase 1
Gene-edited immune cells for AML after transplant
This trial tests a type of immune cell called gamma-delta T cells in people with acute myeloid leukemia who still have minimal residual disease after a stem cell transplant. The goal is to see if these cells can clear the remaining leukemia cells safely and effectively.
BeijingAges 18 years+ - NCT07127289RecruitingPhase 2
Stem cell infusion for low blood counts after CAR-T therapy
This trial tests if giving back your own stored stem cells can help restore low blood cell counts that persist or develop 30 to 90 days after CAR-T therapy for multiple myeloma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07131059Recruiting
Study for MRD-positive AML in remission
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT07132684RecruitingPhase 3
Comparing two chemotherapy plans for older AML patients
This trial compares two different combinations of chemotherapy drugs for older adults (ages 55-75) with newly diagnosed acute myeloid leukemia (AML) who are otherwise healthy enough to tolerate intensive treatment. The goal is to see which combination is more effective and has fewer side effects.
TianjinAges 55–75 - NCT07121140Recruiting
Home blood transfusions for cancer patients
This trial tests whether it is safe to give blood transfusions at home instead of in the hospital. It is for people who need regular blood transfusions for their cancer care.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07115667RecruitingPhase 2
Radiation and antibody therapy for bone plasmacytoma
This trial tests a new combination of radiation therapy and a bispecific antibody (a drug that helps your immune system attack cancer cells) for people with a single bone plasmacytoma that has only a small number of abnormal cells in the bone marrow. It aims to see if this approach can control the disease better than radiation alone.
TianjinAges 18–78 - NCT07115654RecruitingPhase 2
A bispecific antibody trial for POEMS syndrome
This trial tests a new drug, BCMA/CD3 bispecific antibody, for people with POEMS syndrome. The drug helps the immune system attack abnormal plasma cells that cause the disease. It may offer a new treatment option for those who haven't had prior anti-plasma cell therapy.
TianjinAges 18–78 - NCT05294055RecruitingPhase 2
Mecapegfilgrastim to help collect stem cells for transplant
This Phase 2 study tests mecapegfilgrastim with chemotherapy to help your body collect enough peripheral blood stem cells for an autologous transplant (using your own cells). It’s for people with multiple myeloma or certain lymphomas who have already had some response to treatment.
Hefei, AnhuiAges 18–65 - NCT07106736RecruitingPhase 2
CAR-T for newly diagnosed multiple myeloma without transplant
This trial is testing a new immunotherapy treatment using CAR-T cells for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The treatment aims to target and destroy myeloma cells that have BCMA and GPRC5D proteins on their surface.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07109323RecruitingPhase 1/Phase 2
Stem cell transplant plus CAR-T for aggressive myeloma
This trial tests combining a stem cell transplant with a special immune cell therapy (BCMA CAR-T) to treat very aggressive multiple myeloma. The goal is to see if this powerful one-two punch can help people whose myeloma is hard to control.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07106710RecruitingPhase 2
Stem cell transplant plus two targeted therapies for ultra-high-risk myeloma
This trial tests a stem cell transplant followed by two targeted therapies — a BCMA CAR-T and a GPRC5D/CD3 bispecific antibody — to treat newly diagnosed multiple myeloma that has ultra-high-risk features. The goal is to see if this combination can better control the disease.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07106684RecruitingPhase 2
Stem cell transplant with car-t and bi-specific antibody for plasma cell leukemia
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07106671RecruitingPhase 2
Siltuximab for side effects after CAR-T in multiple myeloma
This trial tests if the drug Siltuximab can help control side effects (CRS and ICANS) that sometimes happen after CAR-T treatment for multiple myeloma. It may help patients who develop these symptoms.
TianjinAges 18 years+
Hear when a new Hematology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematology?
- Yes. Clin2 currently lists 574 recruiting hematology studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematology trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematology trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.